Mizuho Reiterates Buy on Sarepta Therapeutics, Maintains $160 Price Target
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Uy Ear has reiterated a 'Buy' rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintained a price target of $160.
September 26, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sarepta Therapeutics has been reiterated with a 'Buy' rating by Mizuho analyst Uy Ear, who maintains a price target of $160.
The reiteration of a 'Buy' rating and maintenance of a high price target by a Mizuho analyst indicates strong confidence in the company's performance. This could potentially lead to increased investor interest and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100